Content
February 2016, Volume 34, Issue 2
- 155-160 Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities
by Miqdad Asaria & Katja Grasic & Simon Walker - 155-160 Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities
by Miqdad Asaria & Katja Grasic & Simon Walker - 161-168 Validation of the Hospital Episode Statistics Outpatient Dataset in England
by Joanna C. Thorn & Emma Turner & Luke Hounsome & Eleanor Walsh & Jenny L. Donovan & Julia Verne & David E. Neal & Freddie C. Hamdy & Richard M. Martin & Sian M. Noble - 161-168 Validation of the Hospital Episode Statistics Outpatient Dataset in England
by Joanna Thorn & Emma Turner & Luke Hounsome & Eleanor Walsh & Jenny Donovan & Julia Verne & David Neal & Freddie Hamdy & Richard Martin & Sian Noble - 169-179 Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data
by Margrét V. Bjarnadóttir & Sana Malik & Eberechukwu Onukwugha & Tanisha Gooden & Catherine Plaisant - 169-179 Understanding Adherence and Prescription Patterns Using Large-Scale Claims Data
by Margrét Bjarnadóttir & Sana Malik & Eberechukwu Onukwugha & Tanisha Gooden & Catherine Plaisant - 181-194 Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
by Caroline Canavan & Joe West & Timothy Card - 181-194 Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
by Caroline Canavan & Joe West & Timothy Card - 195-205 Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease
by Chris Schilling & Duncan Mortimer & Kim Dalziel & Emma Heeley & John Chalmers & Philip Clarke - 195-205 Using Classification and Regression Trees (CART) to Identify Prescribing Thresholds for Cardiovascular Disease
by Chris Schilling & Duncan Mortimer & Kim Dalziel & Emma Heeley & John Chalmers & Philip Clarke - 207-216 Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases
by Eberechukwu Onukwugha & Ran Qi & Jinani Jayasekera & Shujia Zhou - 207-216 Cost Prediction Using a Survival Grouping Algorithm: An Application to Incident Prostate Cancer Cases
by Eberechukwu Onukwugha & Ran Qi & Jinani Jayasekera & Shujia Zhou
January 2016, Volume 34, Issue 1
- 1-3 Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016
by Yot Teerawattananon & Alia Luz - 1-3 Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016
by Yot Teerawattananon & Alia Luz - 5-11 The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?
by James F. O’Mahony & Diarmuid Coughlan - 5-11 The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland’s Health System?
by James O’Mahony & Diarmuid Coughlan - 13-22 Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
by Elamin H. Elbasha & Jagpreet Chhatwal - 13-22 Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers
by Elamin Elbasha & Jagpreet Chhatwal - 23-31 Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
by Hedwig Blommestein & Nigel Armstrong & Steve Ryder & Sohan Deshpande & Gill Worthy & Caro Noake & Rob Riemsma & Jos Kleijnen & Johan Severens & Maiwenn Al - 33-42 The Cost Effectiveness of Docetaxel and Active Symptom Control versus Active Symptom Control Alone for Refractory Oesophagogastric Adenocarcinoma: Economic Analysis of the COUGAR-02 Trial
by David Meads & Andrea Marshall & Claire Hulme & Janet Dunn & Hugo Ford - 43-58 Cost-of-Illness Studies: An Updated Review of Current Methods
by Eberechukwu Onukwugha & Jacquelyn McRae & Alex Kravetz & Stefan Varga & Rahul Khairnar & C. Mullins - 59-76 Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries
by Emelie Heintz & Andreas Gerber-Grote & Salah Ghabri & Francoise F. Hamers & Valentina Prevolnik Rupel & Renata Slabe-Erker & Thomas Davidson - 59-76 Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries
by Emelie Heintz & Andreas Gerber-Grote & Salah Ghabri & Francoise Hamers & Valentina Rupel & Renata Slabe-Erker & Thomas Davidson - 77-90 Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
by William Herring & Isobel Pearson & Molly Purser & Hamid Reza Nakhaipour & Amin Haiderali & Sorrel Wolowacz & Kavisha Jayasundara - 77-90 Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
by William Herring & Isobel Pearson & Molly Purser & Hamid Nakhaipour & Amin Haiderali & Sorrel Wolowacz & Kavisha Jayasundara
December 2015, Volume 33, Issue 12
- 1241-1244 Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
by Livio Garattini & Francesca Ghislandi & Milene Costa - 1245-1253 Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease
by Zobair Younossi & Linda Henry - 1255-1268 Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice
by James O’Mahony & Anthony Newall & Joost Rosmalen - 1269-1279 Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
by Christina Giannopoulou & Eleftherios Sideris & Ros Wade & Thirimon Moe-Byrne & Alison Eastwood & Claire McKenna - 1281-1288 Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?
by Jonathan Karnon & Andrew Partington - 1289-1300 Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment
by Liesbet Wetering & Job Exel & Ana Bobinac & Werner Brouwer - 1301-1310 Cost Effectiveness of Falls and Injury Prevention Strategies for Older Adults Living in Residential Aged Care Facilities
by Jody Church & Marion Haas & Stephen Goodall - 1311-1324 Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
by Florian Gutzwiller & Alena Pfeil & Zanfina Ademi & Patricia Blank & Peter Braunhofer & Thomas Szucs & Matthias Schwenkglenks
November 2015, Volume 33, Issue 11
- 1101-1105 Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values?
by Tessa Peasgood & John Brazier - 1107-1135 Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey
by Dagna Constenla & Cristina Garcia & Noah Lefcourt - 1137-1154 Can The EQ-5D Detect Meaningful Change? A Systematic Review
by Nalin Payakachat & Mir Ali & J. Tilford - 1155-1185 Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review
by Insiya Poonawalla & Rohan Parikh & Xianglin Du & Helena VonVille & David Lairson - 1187-1194 Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
by Emma Simpson & Sarah Davis & Praveen Thokala & Penny Breeze & Peter Bryden & Ruth Wong - 1195-1214 Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index
by Adrian Gheorghe & Tracy Roberts & Karla Hemming & Melanie Calvert - 1215-1228 Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
by Katharina Schremser & Wolf Rogowski & Sigrid Adler-Reichel & Amanda Tufman & Rudolf Huber & Björn Stollenwerk - 1229-1236 Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness
by Mikael Svensson & Fredrik Nilsson & Karl Arnberg
October 2015, Volume 33, Issue 10
- 985-991 Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement
by Stavros Petrou & Oliver Rivero-Arias & Helen Dakin & Louise Longworth & Mark Oppe & Robert Froud & Alastair Gray - 993-1011 The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration
by Stavros Petrou & Oliver Rivero-Arias & Helen Dakin & Louise Longworth & Mark Oppe & Robert Froud & Alastair Gray - 1013-1028 A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations
by Gang Chen & Julie Ratcliffe - 1029-1047 A Systematic Review of the Economic and Humanistic Burden of Gout
by Gemma Shields & Stephen Beard - 1049-1067 Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment
by Gregory Kruse & Bruce Wong & Mei Duh & Patrick Lefebvre & Marie-Hélène Lafeuille & John Fastenau - 1069-1082 Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments
by Neily Zakiyah & Maarten Postma & Philip Baker & Antoinette Asselt - 1083-1090 Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters
by Wanrudee Isaranuwatchai & Maureen Markle-Reid & Jeffrey Hoch - 1091-1100 Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke
by Nobuyoshi Takabayashi & Kyoko Murata & Shiro Tanaka & Koji Kawakami
September 2015, Volume 33, Issue 9
- 887-892 Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation
by Scott Nelson & Daniel Malone & Joanne Lafleur - 893-904 Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
by Nigel Fleeman & Adrian Bagust & Sophie Beale & Angela Boland & Rumona Dickson & Kerry Dwan & Marty Richardson & Yenal Dundar & Helen Davis & Lindsay Banks - 905-924 Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
by Bonny Parkinson & Catherine Sermet & Fiona Clement & Steffan Crausaz & Brian Godman & Sarah Garner & Moni Choudhury & Sallie-Anne Pearson & Rosalie Viney & Ruth Lopert & Adam Elshaug - 925-937 The Economic and Humanistic Burden of Severe Sepsis
by Bogdan Tiru & Ernest DiNino & Abigail Orenstein & Patrick Mailloux & Adam Pesaturo & Abhinav Gupta & William McGee - 939-955 Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review
by Yoko Laurence & Ulla Griffiths & Anna Vassall - 957-965 Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia
by Sabina Sanghera & Emma Frew & Janesh Gupta & Joe Kai & Tracy Roberts - 967-979 A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark
by Anne Vestergaard & Lars Ehlers - 981-982 Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”
by Afschin Gandjour - 983-983 The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”
by Janneke Grutters & Marjolein Asselt & Kalipso Chalkidou & Manuela Joore
August 2015, Volume 33, Issue 8
- 777-781 Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions
by Gerardus Frederix & Hossein Haji Ali Afzali & Erik Dasbach & Robyn Ward - 783-809 Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations
by Roland Diel & Niklas Lampenius & Albert Nienhaus - 811-831 The Economic Costs of Type 2 Diabetes: A Global Systematic Review
by Till Seuring & Olga Archangelidi & Marc Suhrcke - 833-847 Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Matt Stevenson & Abdullah Pandor & John Stevens & Andrew Rawdin & Peter Rice & Jez Thompson & Marsha Morgan - 849-855 Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach
by Paula Lorgelly - 857-865 Characterizing Heterogeneity Bias in Cohort-Based Models
by Elamin Elbasha & Jagpreet Chhatwal - 867-877 A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
by Feng Xie & A. Pickard & Paul Krabbe & Dennis Revicki & Rosalie Viney & Nancy Devlin & David Feeny - 879-882 Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
by Jeffrey Hoch & Jaclyn Beca & Mona Sabharwal & Scott Livingstone & Anthony Fields - 883-886 The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars
by Heather McDonald & Cathy Charles & Laurie Elit & Amiram Gafni
July 2015, Volume 33, Issue 7
- 613-617 For a Step Change to Curb the Obesity Epidemic
by Christian Frois & Pierre-Yves Cremieux - 619-628 Policy Makers’ Views of Obesity-Related Challenges Around the World
by Pierre Cremieux - 629-641 Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications
by Amarpreet Chawla & Chia-Wen Hsiao & Martha Romney & Ricardo Cohen & Francesco Rubino & Philip Schauer & Pierre Cremieux - 643-653 The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
by Charles Baum & Katherine Andino & Eric Wittbrodt & Shelley Stewart & Keith Szymanski & Robin Turpin - 655-672 Obesity in the Context of Aging: Quality of Life Considerations
by Francesco Corica & Giampaolo Bianchi & Andrea Corsonello & Natalia Mazzella & Fabrizia Lattanzio & Giulio Marchesini - 673-689 The Epidemiology of Obesity: A Big Picture
by Adela Hruby & Frank Hu - 691-697 The Effect of Obesity and Chronic Conditions on Medicare Spending, 1987–2011
by Lindsay Allen & Ken Thorpe & Peter Joski - 699-706 Cost-Effectiveness Analysis of Qsymia for Weight Loss
by Eric Finkelstein & Eliza Kruger & Sunil Karnawat - 707-722 Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status
by John Cawley & Chad Meyerhoefer & Adam Biener & Mette Hammer & Neil Wintfeld - 723-734 Do Statins Reduce the Health and Health Care Costs of Obesity?
by Étienne Gaudette & Dana Goldman & Andrew Messali & Neeraj Sood - 735-748 The Economic Burden of Obesity by Glycemic Stage in the United States
by Qian Li & Steven Blume & Joanna Huang & Mette Hammer & Thomas Graf - 749-763 The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation
by Anita Chawla & Ginger Carls & Edmund Deng & Edward Tuttle - 765-776 Preventing Obesity in the USA: Impact on Health Service Utilization and Costs
by Michele Cecchini & Franco Sassi
June 2015, Volume 33, Issue 6
- 537-549 Simulation and Matching-Based Approaches for Indirect Comparison of Treatments
by K. Ishak & Irina Proskorovsky & Agnes Benedict - 551-560 A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
by Hedwig Blommestein & Margreet Franken & Carin Uyl-de Groot - 561-569 Pharmacological Management of Chronic Lower Back Pain: A Review of Cost Effectiveness
by Marion Haas & Richard Abreu Lourenco - 571-579 Welfarism Versus Extra-Welfarism: Can the Choice of Economic Evaluation Approach Impact on the Adoption Decisions Recommended by Economic Evaluation Studies?
by James Buchanan & Sarah Wordsworth - 581-597 Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes
by Jinsong Geng & Hao Yu & Yiwei Mao & Peng Zhang & Yingyao Chen - 599-610 Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program
by Francisco Jódar-Sánchez & Amaia Malet-Larrea & José Martín & Leticia García-Mochón & M. López del Amo & Fernando Martínez-Martínez & Miguel Gastelurrutia-Garralda & Victoria García-Cárdenas & Daniel Sabater-Hernández & Loreto Sáez-Benito & Shalom Benrimoj - 611-611 Erratum to: Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex ® ) for Spasticity in Multiple Sclerosis
by Lanting Lu & Hilary Pearce & Chris Roome & James Shearer & Iain Lang & Ken Stein
May 2015, Volume 33, Issue 5
- 423-433 Economic Evaluations with Agent-Based Modelling: An Introduction
by Jagpreet Chhatwal & Tianhua He - 435-443 Exploring Structural Uncertainty in Model-Based Economic Evaluations
by Hossein Haji Ali Afzali & Jonathan Karnon - 445-455 A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare Decisions
by Henk Broekhuizen & Catharina Groothuis-Oudshoorn & Janine Til & J. Hummel & Maarten IJzerman - 457-466 The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence
by Ros Wade & Ana Duarte & Mark Simmonds & Rocio Rodriguez-Lopez & Steven Duffy & Nerys Woolacott & Eldon Spackman - 467-488 Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease
by Kunal Srivastava & Deepika Thakur & Sheetal Sharma & Yogesh Punekar - 489-509 Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?
by Saskia Schawo & Annemarie Kolk & Clazien Bouwmans & Lieven Annemans & Maarten Postma & Jan Buitelaar & Michel Agthoven & Leona Hakkaart-van Roijen - 511-520 Cost of Acute Stroke Care for Patients with Atrial Fibrillation Compared with Those in Sinus Rhythm
by Ali Ali & Joanne Howe & Ahmed Abdel-Hafiz - 521-531 Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand
by Naruemon Bamrungsawad & Nathorn Chaiyakunapruk & Nilawan Upakdee & Chayanin Pratoomsoot & Rosarin Sruamsiri & Piyameth Dilokthornsakul - 533-534 Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis
by Sabina Sanghera & Emma Frew & Tracy Roberts - 535-536 Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration
by Don Husereau & Michael Drummond & Stavros Petrou & Dan Greenberg & Josephine Mauskopf & Federico Augustovski & Andrew Briggs & David Moher & Elizabeth Loder & Chris Carswell
April 2015, Volume 33, Issue 4
- 285-325 Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus
by Fernando Antonanzas & Carmen Lozano & Carmen Torres - 327-340 Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis
by Wei Zhang & Nazrul Islam & Canice Ma & Aslam Anis - 341-353 Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies
by Huajie Jin & Paul McCrone - 355-366 An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis
by Rachael Hunter & Gianluca Baio & Thomas Butt & Stephen Morris & Jeff Round & Nick Freemantle - 367-380 Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
by Thomas Delea & Jordan Amdahl & Alice Wang & Mayur Amonkar & Marroon Thabane - 381-393 Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX ® ) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
by Rizwan Hamid & Clara Loveman & Jim Millen & Denise Globe & Catherine Corbell & Danielle Colayco & Sanja Stanisic & Dmitry Gultyaev - 395-408 Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control
by Andrej Janzic & Mitja Kos - 409-422 Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy
by Essè Akpo & Karin Cerri & Joris Kleintjens
March 2015, Volume 33, Issue 3
- 191-192 Is it Time to Update Societal Value Sets for Preference-Based Measures of Health?
by A. Pickard - 193-203 Resource Modelling: The Missing Piece of the HTA Jigsaw?
by Praveen Thokala & Simon Dixon & Beate Jahn - 205-224 A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
by Mickaël Hiligsmann & Silvia Evers & Wafa Ben Sedrine & John Kanis & Bram Ramaekers & Jean-Yves Reginster & Stuart Silverman & Caroline Wyers & Annelies Boonen - 225-233 Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective
by Michael Holmes & Sarah Davis & Emma Simpson - 235-241 Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?
by Heather McDonald & Cathy Charles & Laurie Elit & Amiram Gafni - 243-253 Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study
by Bohdan Nosyk & Viviane Lima & Guillaume Colley & Benita Yip & Robert Hogg & Julio Montaner - 255-269 Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
by Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe - 271-283 Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
by Alexander Mensch & Stephanie Stock & Björn Stollenwerk & Dirk Müller
February 2015, Volume 33, Issue 2
- 83-87 Are We Lacking Economic Evaluations in Gastric Cancer Treatment?
by Alyson Mahar & Abraham El-Sedfy & Savtaj Brar & Ana Johnson & Natalie Coburn - 89-95 Cost-Value Analysis of Health Interventions: Introduction and Update on Methods and Preference Data
by Erik Nord - 97-103 A Primer on Marginal Effects—Part II: Health Services Research Applications
by E. Onukwugha & J. Bergtold & R. Jain - 105-121 A Practical Guide to Value of Information Analysis
by Edward Wilson - 123-135 Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies
by Marieke Krol & Jocé Papenburg & Job van Exel - 137-148 Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal
by Janette Greenhalgh & Adrian Bagust & Angela Boland & James Oyee & Nicola Trevor & Sophie Beale & Yenal Dundar & Juliet Hockenhull & Chris Proudlove & Susan O’Reilly - 149-161 Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK
by P. McEwan & H. Bennett & T. Ward & K. Bergenheim - 163-177 Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis
by Laura Sawyer & David Wonderling & Karina Jackson & Ruth Murphy & Eleanor Samarasekera & Catherine Smith - 179-190 Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
by Patricia Blank & Martin Filipits & Peter Dubsky & Florian Gutzwiller & Michael Lux & Jan Brase & Karsten Weber & Margaretha Rudas & Richard Greil & Sibylle Loibl & Thomas Szucs & Ralf Kronenwett & Matthias Schwenkglenks & Michael Gnant
January 2015, Volume 33, Issue 1
- 1-4 Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy
by Janneke Grutters & Marjolein Asselt & Kalipso Chalkidou & Manuela Joore - 5-11 Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods
by Sebastian Hinde & Eldon Spackman - 13-23 Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
by Nigel Fleeman & Adrian Bagust & Sophie Beale & Kerry Dwan & Rumona Dickson & Chris Proudlove & Yenal Dundar - 25-30 A Primer on Marginal Effects—Part I: Theory and Formulae
by Eberechukwu Onukwugha & Jason Bergtold & Rahul Jain - 31-48 Estimating Productivity Costs in Health Economic Evaluations: A Review of Instruments and Psychometric Evidence
by Kenneth Tang - 49-59 Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation
by Wolf Rogowski & Katherine Payne & Petra Schnell-Inderst & Andrea Manca & Ursula Rochau & Beate Jahn & Oguzhan Alagoz & Reiner Leidl & Uwe Siebert - 61-69 Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project
by Ariel Beresniak & Antonieta Medina-Lara & Jean Auray & Alain Wever & Jean-Claude Praet & Rosanna Tarricone & Aleksandra Torbica & Danielle Dupont & Michel Lamure & Gerard Duru - 71-81 Reduce Mortality Risk Above All Else: A Discrete-Choice Experiment in Acute Coronary Syndrome Patients
by Axel Mühlbacher & Susanne Bethge
December 2014, Volume 32, Issue 12
- 1151-1152 Cost of Illness: An Ongoing Battle Worth Fighting
by Paul Greenberg - 1153-1155 “Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies
by Steven Kymes - 1157-1170 A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials
by Rita Faria & Manuel Gomes & David Epstein & Ian White - 1171-1183 Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
by Nicholas Latimer & Christopher Carroll & Ruth Wong & Paul Tappenden & Michael Venning & Raashid Luqmani - 1185-1199 A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions
by Rachel Elliott & Koen Putman & James Davies & Lieven Annemans - 1201-1212 A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments
by Andrew Messali & Reginald Villacorta & Joel Hay - 1213-1229 The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review
by Erika Wissinger & Ingolf Griebsch & Juliane Lungershausen & Michael Byrnes & Karin Travers & Chris Pashos - 1231-1243 Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer
by Steven Alberts & Tiffany Yu & Robert Behrens & Lindsay Renfro & Geetika Srivastava & Gamini Soori & Shaker Dakhil & Rex Mowat & John Kuebler & George Kim & Miroslaw Mazurczak & John Hornberger - 1245-1246 Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
by Afschin Gandjour - 1247-1247 Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
by A. Newall & M. Jit & R. Hutubessy - 1249-1250 Objectivity and Equity: Clarity Required. A Response to Hill and Olson
by Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe
November 2014, Volume 32, Issue 11
- 1035-1037 Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?
by Surrey Walton & Glen Schumock - 1039-1041 NICE, Social Values, and Balancing Objectivity and Equity
by Suzanne Hill & Leslie Olson - 1043-1053 Some Inconsistencies in NICE’s Consideration of Social Values
by Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe - 1055-1061 Through a Glass Darkly: Economics and Personalised Medicine
by Alan Haycox & Munir Pirmohamed & Claire McLeod & Rachel Houten & Sarah Richards - 1063-1078 Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome
by Fotini Gialama & Evangelia Miloni & Nikos Maniadakis - 1079-1091 Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review
by Patrick Zueger & Neil Schultz & Todd Lee - 1093-1104 The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
by Christina Yeung & Tuan Dinh & Joseph Lee - 1105-1114 A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States
by Bijal Patel & Patricia Audet - 1115-1127 Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment
by Peter Ghijben & Emily Lancsar & Silva Zavarsek - 1129-1139 Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease
by Shien Guo & Denis Getsios & Nikhil Revankar & Peng Xu & Gwilym Thompson & Joel Bobula & Loretto Lacey & Maren Gaudig - 1141-1145 The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees
by Manuel Arias & Francisco Díez
October 2014, Volume 32, Issue 10
- 937-942 Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following Its 20th Anniversary
by Robin Gauld - 943-950 Decision-Analytic Models: Current Methodological Challenges
by J. Caro & Jörgen Möller - 951-965 Reconceptualising the External Validity of Discrete Choice Experiments
by Emily Lancsar & Joffre Swait - 967-979 Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models
by Paul Tappenden & James Chilcott - 981-993 Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Lymphocytic Leukaemia: A Review of Methods to Model Disease Outcomes and Estimate Utility
by Kevin Marsh & Peng Xu & Panagiotis Orfanos & James Gordon & Ingolf Griebsch - 995-1004 Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes
by Zafar Zafari & Kristian Thorlund & J. FitzGerald & Carlo Marra & Mohsen Sadatsafavi - 1005-1013 Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with Stage III Colon Cancer
by David Lairson & Rohan Parikh & Janice Cormier & Wenyaw Chan & Xianglin Du - 1015-1028 Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis
by An Tran-Duy & Annelies Boonen & Wietske Kievit & Piet Riel & Mart Laar & Johan Severens - 1029-1029 Erratum to: Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
by Matt Stevenson & Peter Selby - 1031-1033 Comment on “Ahead of Its Time? Reflecting on New Zealand’s Pharmac Following its 20th Anniversary”
by Scott Metcalfe & Rachel Grocott & Dilky Rasiah
September 2014, Volume 32, Issue 9
- 815-817 Hospital-Based Health Technology Assessment: Insights from New Zealand
by Stephen Munn - 819-824 Hospital-Based Health Technology Assessment: Developments to Date
by Marie-Pierre Gagnon - 825-839 HTA Agencies Facing Model Biases: The Case of Type 2 Diabetes
by Véronique Raimond & Jean-Michel Josselin & Lise Rochaix - 841-851 The Burden of Disease in Rheumatoid Arthritis
by Till Uhlig & Rikke Moe & Tore Kvien - 853-864 Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
by Kevin Marsh & Peng Xu & Panagiotis Orfanos & Agnes Benedict & Kamal Desai & Ingolf Griebsch - 865-882 The Economic Burden of Head and Neck Cancer: A Systematic Literature Review
by Erika Wissinger & Ingolf Griebsch & Juliane Lungershausen & Talia Foster & Chris Pashos - 883-902 Discrete Choice Experiments in Health Economics: A Review of the Literature
by Michael Clark & Domino Determann & Stavros Petrou & Domenico Moro & Esther Bekker-Grob - 903-917 Cost Effectiveness of Darunavir/ritonavir Combination Antiretroviral Therapy for Treatment-Naive Adults with HIV-1 Infection in Canada
by Anita Brogan & Erik Smets & Josephine Mauskopf & Sarah Manuel & Ines Adriaenssen - 919-936 Pharmacoeconomic Evaluation of Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement in Spain
by Antonio Gómez-Outes & Cristina Avendaño-Solá & Ana Terleira-Fernández & Emilio Vargas-Castrillón
August 2014, Volume 32, Issue 8
- 725-727 Transparency in Reimbursement Decisions: In Whose Best Interest?
by Tania Stafinski & Devidas Menon - 729-733 Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?
by James Chambers - 735-743 Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider
by Matt Stevenson & Peter Selby - 745-758 Economic Evaluations of Gastroesophageal Reflux Disease Medical Management
by Andrew Gawron & Dustin French & John Pandolfino & Colin Howden - 759-773 A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis
by Ayse Kuspinar & Nancy Mayo - 775-787 Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
by Alex Diamantopoulos & A. Finckh & T. Huizinga & D. Sungher & L. Sawyer & D. Neto & F. Dejonckheere - 789-799 The Better than Dead Method: Feasibility and Interpretation of a Valuation Study
by R. Hoorn & A. Donders & M. Oppe & P. Stalmeier - 801-813 A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding
by Rosarin Sruamsiri & Piyameth Dilokthornsakul & Chayanin Pratoomsoot & Nathorn Chaiyakunapruk
July 2014, Volume 32, Issue 7
- 613-615 NICE’s Cost-Effectiveness Range: Should it be Lowered?
by J. Raftery - 617-626 Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs
by R. Diel & N. Lampenius - 627-637 Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease
by Laura Burgers & William Redekop & Johan Severens - 639-650 A Review of the Economics of Treating Clostridium difficile Infection
by Kari Mergenhagen & Amy Wojciechowski & Joseph Paladino - 651-680 Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review
by Fabrice Smieliauskas & Chun-Ru Chien & Chan Shen & Daniel Geynisman & Ya-Chen Shih - 681-691 Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study
by Pieter Dylst & Arnold Vulto & Steven Simoens - 693-706 Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales
by Kamran Khan & Stavros Petrou & Oliver Rivero-Arias & Stephen Walters & Spencer Boyle - 707-724 Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand
by Rachel Webber-Foster & Giorgi Kvizhinadze & Gareth Rivalland & Tony Blakely
June 2014, Volume 32, Issue 6
- 521-523 Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?
by Josephine Mauskopf - 525-531 Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines
by A. Newall & M. Jit & R. Hutubessy - 533-546 Methods for Adjusting for Bias Due to Crossover in Oncology Trials
by K. Ishak & Irina Proskorovsky & Beata Korytowsky & Rickard Sandin & Sandrine Faivre & Juan Valle - 547-558 When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES
by Jonathan Karnon & Hossein Haji Ali Afzali - 559-572 Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
by Shien Guo & Christopher Pelligra & Catherine Saint-Laurent Thibault & Luis Hernandez & Anuraag Kansal - 573-590 Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)
by Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery - 591-599 Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
by Klazien Matter-Walstra & Dirk Klingbiel & Thomas Szucs & Bernhard Pestalozzi & Matthias Schwenkglenks - 601-612 Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
by Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp
May 2014, Volume 32, Issue 5
- 425-427 Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now
by Wei Zhang & Aslam Anis - 429-442 How to Select the Right Cost-Effectiveness Model?
by H. Haalen & J. Severens & A. Tran-Duy & A. Boonen - 443-455 Is Individualized Medicine More Cost-Effective? A Systematic Review
by Maximilian Hatz & Katharina Schremser & Wolf Rogowski